Who Owns Amphastar Pharmaceuticals Company?

Amphastar Pharmaceuticals Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who owns Amphastar Pharmaceuticals today?

Amphastar transitioned from a founder-led sterile-injectables maker to a NASDAQ-listed specialty pharma after its 2014 IPO, expanding into branded and generic injectables with contract manufacturing and respiratory assets.

Ownership combines founding insiders with significant institutional investors; position changes reflect IPO allocations, insider transactions, and M&A activity shaping control and governance.

See a product overview: Amphastar Pharmaceuticals Porter's Five Forces Analysis

Founders and Early Ownership of Amphastar Pharmaceuticals were concentrated with co-founders Jack Y. Zhang, Ph.D., and Mary Z. Luo, Ph.D., who led scientific and operational development and retained control through direct holdings and controlled entities; early employees and friends-and-family held modest option pools with standard vesting and ROFR provisions.

Founding team

Co-founded by Jack Y. Zhang, Ph.D., and Mary Z. Luo, Ph.D., with a small scientific leadership team and early staff supporting sterile manufacturing and analytical development.

Equity concentration

Zhang and Luo controlled the majority of equity from inception through the pre-IPO period (1996–2013) via direct holdings and controlled entities.

Pre-IPO ownership

SEC disclosures before the 2014 IPO showed the founders together held well over 50% pre-offering, indicating limited outside venture capital.

Early financing strategy

Growth funded mainly through operations, debt, and selective strategic partnerships rather than large VC rounds, preserving founder control.

Employee equity

Friends-and-family and senior employees received modest option pools with typical four-year vesting and standard buy-sell/ROFR provisions under equity plans.

Governance and control

No widely reported early founder disputes; consolidated control aligned with long-term build-out of sterile manufacturing before scaling distribution.

SEC filings and the 2014 IPO prospectus remain primary factual sources for pre-offering ownership percentages and show founders retained majority control while later public filings list Amphastar shareholders and institutional positions evolving post-IPO; see further context in Competitors Landscape of Amphastar Pharmaceuticals.

Key facts — founders & early ownership

Founders held concentrated ownership and used conservative external funding to preserve control; early option programs were modest and standard for the industry.

• Founders Zhang and Luo held well over 50% pre-IPO per SEC disclosures.
• Early employee options typically used four-year vesting schedules and ROFR clauses.
• Limited venture capital; funding via operations, debt, and strategic partnerships prioritized.
• Post-IPO, institutional ownership and Amphastar shareholders evolved — consult 2024–2025 filings for current breakdowns.

Amphastar Pharmaceuticals SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Key events reshaped Amphastar Pharmaceuticals ownership from founder-led, pre-2010s expansion through the June 25, 2014 IPO and into the 2023 Baqsimi acquisition, driving concentration among institutional investors and elevating insider and passive-holder governance focus.

Ownership shifts supported strategic pivots—debt-funded acquisitions and a growing retail/institutional float increased emphasis on governance and board independence while preserving founder influence.

Current Major Stakeholders Snapshot

As of 2024–2025 filings, ownership shows concentrated institutional stakes with meaningful insider holdings by founders and senior executives.

• Founders/insiders: Jack Y. Zhang and Mary Z. Luo combined in the low-to-mid double-digit percentage range (proxy ranges reflect low-to-mid teens)
• Institutions: Vanguard Group and BlackRock typically hold mid-to-high single-digit percentages each; Dimensional, State Street, and healthcare-focused active funds also prominent
• Public float: Broad retail and additional institutional holders; passive ownership rise increased governance focus
• Transaction impact: 2023 Baqsimi deal (~$1.08 billion) financed without equity issuance, limiting immediate dilution

For more on Amphastar Pharmaceuticals business focus and market positioning see Target Market of Amphastar Pharmaceuticals

Amphastar Pharmaceuticals PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Amphastar Pharmaceuticals' board (2024–2025) blends co‑founders and independent directors, led by CEO Jack Y. Zhang, Ph.D., and co‑founder Mary Z. Luo, Ph.D., with independent committee chairs meeting NASDAQ independence standards.

The board size and committee composition are aligned with governance best practices; voting uses a single‑class common stock, one‑share‑one‑vote model, with founders' influence deriving from shareholdings and tenure rather than special voting rights.

Board control and voting facts (2024–2025)

Key governance and ownership points affecting who owns Amphastar Pharmaceuticals and Amphastar shareholders.

• Voting structure: single‑class common stock — one vote per share, no dual‑class or founder super‑voting disclosed
• Founders (Zhang, Luo) hold meaningful insider stakes; influence via ownership and executive roles rather than golden shares
• No high‑profile proxy contests reported through mid‑2025; shareholder focus on capital allocation after the Baqsimi transaction
• Shareholder engagement topics: leverage metrics, pipeline prioritization, and executive compensation alignment with performance

Major Amphastar institutional investors and Amphastar largest shareholders as of mid‑2025 include mutual funds and asset managers reported in the 2025 proxy and 13F filings; for detailed holders and percentage of shares owned by insiders at Amphastar, see the company’s latest proxy statement and SEC beneficial owner filings and this analysis: Marketing Strategy of Amphastar Pharmaceuticals

Amphastar Pharmaceuticals Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Recent ownership trends at Amphastar Pharmaceuticals show rising institutional stakes after the 2023–2025 Baqsimi acquisition, with passive indexation and routine insider activity reshaping the shareholder mix while founders retain meaningful but non-controlling positions.

Analyst commentary and company filings through mid‑2025 indicate continued BD and R&D spend, prioritizing integration and growth in endocrinology/critical care while aiming to reduce leverage; ownership may shift further toward institutions if market cap and index weights increase.

Institutional concentration rises

Index inclusion lifted passive holdings; Vanguard, BlackRock, State Street and Dimensional increased positions by 2025, reinforcing passive voting blocs.

Insider activity remains measured

Executives used routine 10b5‑1 plans and option exercises; founders still hold meaningful stakes but face gradual dilution as float and index ownership grow.

Leverage and capital allocation focus

Deal funded with cash plus debt increased leverage metrics; management and analysts cite deleveraging from cash flow and restrained capital returns while funding integration and R&D.

Public listing intact

No indications of privatization through mid‑2025; outlook points to continued public status and potential further institutional ownership if market cap and index weights rise.

For fuller context on strategy and ownership implications see Growth Strategy of Amphastar Pharmaceuticals

Amphastar Pharmaceuticals Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔